Effect of voriconazole on the pharmacokinetics of diclofenac

Fundamental and Clinical Pharmacology

Volumn 21, Issue 6, 2007, Pages 651-656

  Hynninen, Ville Veikko ^a   Olkkola, Klaus T ^a   Leino, Kari ^a   Lundgren, Stefan ^b   Neuvonen, Pertti J ^c   Rane, Anders ^b   Valtonen, Mika ^a   Laine, Kari ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cytochrome P450 (CYP) enzyme; Diclofenac; Drug interaction; Metabolism; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DICLOFENAC; DICLOMEX; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; ENZYME INHIBITION; FIRST PASS EFFECT; HALF LIFE TIME; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DICLOFENAC; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; PYRIMIDINES; TRIAZOLES;

EID: 36348940960     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00516.x     Document Type: Article

References (26)

1. Willis J.V., Kendall M.J., Flinn R.M., Thornhill D.P., Welling P.G. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur. J. Clin. Pharmacol. (1979) 16, 405 410.
2. Hinz B., Chevts J., Renner B. et al. Bioavailability of diclofenac potassium at low doses. Br. J. Clin. Pharmacol. (2005) 59, 80 84
3. Stierlin H., Faigle J.W., Sallmann A. et al. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica (1979) 9, 601 610.
4. Geiger U.P., Degen P.H., Sioufi A. Quantitative assay of diclofenac in biological material by gas-liquid chromatography. J. Chromatogr. (1975) 3, 293 298.
5. Leemann T., Transon C., Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. (1993) 52, 29 34.
6. Bort R., Mace K., Boobis A., Gomez-Lechon M.J., Pfeifer A., Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol. (1999) 58, 787 796
7. Shen S., Marchick M.R., Davis M.R., Doss G.A., Pohl L.R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol. (1999) 12, 214 222
8. Purkins L., Wood N., Kleinermans D., Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. (2003) 56, 24 29.
9. Purkins L., Wood N., Ghahramani P., Love E.R., Eve M.D., Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. (2003) 56, 37 44.
10. Saari T.I., Laine K., Leino K., Valtonen M., Neuvonen P.J., Olkkola K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin. Pharmacol. Ther. (2006) 79, 362 370.
11. Lansdorp D., Janssen T.J., Guelen P.J., Vree T.B. High-performance liquid chromatographic method for the determination of diclofenac and its hydroxy metabolites in human plasma and urine. J. Chromatogr. (1990) 528, 487 494.
12. Zecca L., Ferrario P., Costi P. Determination of diclofenac and its metabolites in plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. (1991) 567, 425 432.
13. Gage R., Stopher D.A. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. (1998) 17, 1449 1453.
14. Pennick G.J., Clark M., Sutton D.A., Rinaldi M.G. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob. Agents Chemother. (2003) 47, 2348 2350.
15. Kovarik J.M., Mueller E.A., Gerbeau C., Tarral A., Francheteau P., Guerret M. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J. Clin. Pharmacol. (1997) 37, 336 343.
16. Transon C., Leemann T., Vogt N., Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. (1995) 58, 412 417.
17. Hynninen V.V., Olkkola K.T., Leino K. et al. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)- and R-(-)-Ibuprofen. Antimicrob. Agents. Chemother. (2006) 50, 1967 1972.
18. Black D.J., Kunze K.L., Wienkers L.C. et al. Warfarin-fluconazole. II. A metabolically based drug interaction in vivo studies. Drug Metab Dispos (1996) 24, 422 428.
19. Kumar S., Samuel K., Subramanian R. et al. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J. Pharmacol. Exp. Ther. (2002) 303, 969 978.
20. King C., Tang W., Ngui J., Tephly T., Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci. (2001) 61, 49 53.
21. Uchaipichat V., Winner L.K., Mackenzie P.I., Elliot D.J., Williams J.A., Miners J.O. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol (2006) 61, 427 439.
22. Brenner S.S., Herrlinger C., Dilger K. et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet. (2003) 42, 283 292.
23. Kirchheiner J., Meineke I., Steinbach N., Meisel C., Roots I., Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. (2003) 55, 51 61.
24. Yasar U., Eliasson E., Forslund-Bergengren C., Tybring G., Gadd M., Sjoqvist F. et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol. (2001) 57, 729 735.
25. Helin-Salmivaara A., Virtanen A., Vesalainen R. et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur. Heart J (2006) 27, 1657 1663.
26. Solomon D.H., Avorn J., Sturmer T., Glynn R.J., Mogun H., Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. (2006) 54, 1378 1389.